Jeremy Rubinstein

18PUBLICATIONS
83CO-AUTHORS
AutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursGene and molecular therapyNeonatology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|May 15, 2026
Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates.

|Sep 24, 2025
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.

Jeremy D Rubinstein, Giang Pham, Anusha Sridharan

|Apr 07, 2025
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

Sara K Silbert, Alexander W Rankin, Chloe N Hoang

|Mar 22, 2025
Posttransplant EBV-Positive Smooth Muscle Tumors in Children, Adolescents, and Young Adults: A Multi-Institution Experience.

Meghan Haney, Kaitlin J Devine, Ana C Xavier

|Jul 31, 2024
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.

Francis R LeBlanc, Erin H Breese, Karen C Burns

|Feb 23, 2023
Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.

Thomas J Galletta, Jeremy D Rubinstein, Christa Krupski

Pageof 3

Frequent Collaborators

3 joint publications

Christopher E Dandoy

3 joint publications

Lauren Pommert

3 joint publications

Michael S Grimley

2 joint publications

Joseph Pressey